PLX - Protalix Biotherapeutics Inc.

PLX Stock Chart

PLX Profile

Protalix BioTherapeutics, Inc., a pioneering biopharmaceutical firm, specializes in advancing recombinant therapeutic proteins using its innovative ProCellEx plant cell-based protein expression system. Operating across the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and other international markets, the company focuses on developing and commercializing novel treatments for a range of medical conditions.

One of its flagship products, Elelyso, addresses Gaucher disease, showcasing Protalix's commitment to providing effective therapies for rare and serious diseases. The company's robust pipeline includes PRX-102, nearing the final stages of clinical trials for Fabry disease treatment. Additionally, PRX-110, a proprietary plant cell-derived form of human deoxyribonuclease I, has completed phase IIa trials for cystic fibrosis treatment.

Protalix BioTherapeutics also advances PRX-115, a plant cell-expressed recombinant PEGylated Uricase targeting gout management, and PRX-119, a PEGylated recombinant human DNase I for diseases related to NETs (neutrophil extracellular traps). Leveraging strategic partnerships with industry leaders like Pfizer, Fundacão Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A., the company accelerates its research and development initiatives while expanding its global footprint.

Founded in 1993 and headquartered in Hackensack, New Jersey, Protalix BioTherapeutics remains dedicated to leveraging cutting-edge biotechnology to enhance treatment options and improve outcomes for patients worldwide, particularly those facing challenging and underserved medical conditions.

PLX Revenue Chart

PLX Earnings

Analyst Ratings